$TCBP Announces Grant of European #Patent for Targeting of Microbial, #Oncological, and Viral Indications using Modified Gamma Delta T Cells
https://t.co/jXHHjENZzd
$TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
The company is expected to reduce core operational burn by 55% when compared to 2024
https://t.co/Nhg7ODF5e2
🔮 2025 is going to be a big year for #biotech. On @BBCNews, our CEO @sajithw explains why the industry is on the cusp of a faster, more automated, and #AI-driven future.
📺 Watch the full interview: https://t.co/jvgWckvVK2
$TCBP Announces General Meeting of Shareholders to Approve One-Time #Shareholder#Dividend
The dividend is expected to be declared on December 30, 2024, and payable to shareholders who own the Company's stock at the close of trading on January 02, 2025.
https://t.co/RQp7y2PqB1
$TCBP Partners with @CareDx, Inc. to Support #ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
https://t.co/etMewB5Fbb
$TCBP Provides Quarterly Update on the #ACHIEVE (UK) #ClinicalTrial
- Positive safety data, allowing for exploration of higher TCB008 doses
- 4 UK-based clinical sites recruiting patients, with a further 2 sites expected in H1 2025
https://t.co/GWJKKhZILS
@ChYs618470 This is a tool used by all biotechs and most companies for capital access when there are moves in the market. Having this shelf in place allows future financings to be LESS dilutive, as there is not a signal to the market, and we can be opportunistic.
Our F3 filing (shelf) is NOT immediately dilutive. It's a placeholder that allows us to be opportunistic about good news with a positive market reaction. Filings, like the one we filed on Weds, are normal business practices for biotechs that are fundamental to accessing capital.
Congrats to @PoseidaThera on being acquired by @Roche. After such a long freeze, it's great to see M&A activity in the Cell Therapy Space.
https://t.co/JBwaiVX98T